KUKU

KU ScholarWorks

  • myKU
  • Email
  • Enroll & Pay
  • KU Directory
    • Login
    View Item 
    •   KU ScholarWorks
    • Dissertations and Theses
    • Dissertations
    • View Item
    •   KU ScholarWorks
    • Dissertations and Theses
    • Dissertations
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    The chemokine CCL2/CCR2 signaling mediates cancer associated fibroblasts-cancer cells interaction and promotes basal-like breast cancer progression

    Thumbnail
    View/Open
    Available after: 2019-12-31 (2.808Mb)
    Issue Date
    2017-12-31
    Author
    Yao, Min
    Publisher
    University of Kansas
    Format
    131 pages
    Type
    Dissertation
    Degree Level
    Ph.D.
    Discipline
    Pathology & Laboratory Medicine
    Rights
    Copyright held by the author.
    Metadata
    Show full item record
    Abstract
    Breast cancer is the most common cancer diagnosed in women in the United States. The basal-like breast cancer subtype represents about 12% of breast cancer and has the worst outcome in patients due to lack of effective therapies. Tumor stroma plays an important role in cancer progression. Cancer associated fibroblasts (CAFs) are the most abundant stromal cells in breast cancer, but their function in cancer progression has not been fully understood. We previously identified that the chemokine CCL2 was highly expressed in breast cancer associated fibroblasts. CCL2 is known to recruit monocyte/macrophage and promotes cancer progression. We previously found that recombinant CCL2 can directly signal to breast cancer cells and promote cell survival and invasion in vitro. In this study, we aimed to determine the functional importance of CCL2 signaling mediated fibroblast-cancer cell interactions in the breast cancer progression. We evaluated the expression of CCL2 and fibroblast marker Fsp1 in breast cancer tissue microarray containing 427 samples by immunohistochemistry. Expression of CCL2 and Fsp1 were co-upregulated in invasive ductal carcinoma compared to normal breast. High stromal CCL2 expression associated with reduced recurrence free survival in the basal-like subtype. Further data mining in the breast cancer TCGA and METABRIC datasets revealed that the CCL2/CCR2 pair expressed highest in the basal-like subtype. We confirmed high CCL2 expression from CAFs isolated from primary human and mouse breast cancer samples. CAFs with high CCL2 expression significantly promoted xenograft growth when co-grated with human basal-like breast cancer MCF10A-CA1D cell line. Reduction of CCL2 expression by CRISPR mutation or shRNA knockdown in human or mouse CAFs significantly reduced tumor growth in the co-graft model. Fibroblasts condition medium or recombinant CCL2 directly promoted CA1D cancer cell growth in vitro. Mutation of the CCL2 receptor CCR2 receptor in CA1D cancer cell significantly reduced cancer cells growth in vitro and in vivo in response to CCL2 stimulation. The CCL2/CCR2 signaling activated PKC and SRC pathways in cancer cells, and contributed to growth promotion. We aimed to test the therapeutic efficacy by blocking CCL2 in breast cancer mouse model through continuous delivery of CCL2 neutralizing antibody. Despite the steady delivery of the antibody, CCL2 blocking did not significantly affect tumor progression. Examination of CCL2 level in blood and tumor sites revealed that CCL2 blocking significantly induced higher free CCL2 level, which may contribute to lack of efficacy. In summary, our studies have showed that CCL2 derived from cancer associated fibroblasts plays an important role in basal-like breast cancer progression. Direct signaling to cancer cells via CCR2 is an important mechanism in CCL2 function. Thus, the CCL2/CCR2 signaling may serve as potential therapeutic targets in basal-like breast cancer. CCL2 blocking by neutralizing antibody can lead to undesired increased CCL2 level, and alternative targeting approaches are needed to achieve therapeutic efficacy.
    URI
    http://hdl.handle.net/1808/27825
    Collections
    • KU Med Center Dissertations and Theses [464]
    • Dissertations [4473]

    Items in KU ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.


    We want to hear from you! Please share your stories about how Open Access to this item benefits YOU.


    Contact KU ScholarWorks
    785-864-8983
    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    785-864-8983

    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    Image Credits
     

     

    Browse

    All of KU ScholarWorksCommunities & CollectionsThis Collection

    My Account

    LoginRegister

    Statistics

    View Usage Statistics

    Contact KU ScholarWorks
    785-864-8983
    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    785-864-8983

    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    Image Credits
     

     

    The University of Kansas
      Contact KU ScholarWorks
    Lawrence, KS | Maps
     
    • Academics
    • Admission
    • Alumni
    • Athletics
    • Campuses
    • Giving
    • Jobs

    The University of Kansas prohibits discrimination on the basis of race, color, ethnicity, religion, sex, national origin, age, ancestry, disability, status as a veteran, sexual orientation, marital status, parental status, gender identity, gender expression and genetic information in the University’s programs and activities. The following person has been designated to handle inquiries regarding the non-discrimination policies: Director of the Office of Institutional Opportunity and Access, IOA@ku.edu, 1246 W. Campus Road, Room 153A, Lawrence, KS, 66045, (785)864-6414, 711 TTY.

     Contact KU
    Lawrence, KS | Maps